Michael Piatak

TL;DR: An RNA virus, designated hepatitis G virus (HGV), was identified from the plasma of a patient with chronic hepatitis and extension from an immunoreactive complementary DNA clone yielded the entire genome, encoding a polyprotein of 2873 amino acids.

TL;DR: It is reported that SIV vaccines that include rhesus cytomegalovirus (RhCMV) vectors establish indefinitely persistent, high-frequency, SIV-specific effector memory T-cell (TEM) responses at potential sites of SIV replication in rhesu macaques and stringently control highly pathogenic SIVMAC239 infection early after mucosal challenge.

TL;DR: Data suggest a new paradigm for AIDS vaccine development—vaccines capable of generating and maintaining HIV-specific TEM cells might decrease the incidence of HIV acquisition after sexual exposure.

TL;DR: It is shown that regardless of the route of challenge, RhCMV/SIV vector-elicited immune responses control SIVmac239 after demonstrable lymphatic and haematogenous viral dissemination, and that replication-competent SIV persists in several sites for weeks to months, providing compelling evidence for progressive clearance of a pathogenic lentiviral infection.

TL;DR: Examination of two new antibodies directed to the CD4-binding site and the V3 region for their ability to block infection and suppress viraemia in macaques infected with the R5 tropic simian–human immunodeficiency virus (SHIV)-AD8 indicates that immunotherapy or a combination of immunotherapy plus conventional antiretroviral drugs might be useful as a treatment for chronically HIV-1-infected individuals experiencing immune dysfunction.